Floatz logo

Zimberelimab

Solid Tumor, Unspecified, Adult

Arcus Biosciences, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Solid Tumor, Unspecified, Adult cohort.

Asset / SponsorPhaseRating
rc48-adc
Hutchmed
Phase 1/2CCC
Mpb-1734
MegaPro Biomedical Co. Ltd.
Phase 1/2CCC
Fruquintinib
Hutchmed
Phase 1/2CCC
Tislelizumab
Hutchmed
Phase 1/2CCC
ad1208
Avelos Therapeutics Inc.
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Zimberelimab is also rated in:

Androgen-Resistant Prostatic NeoplasmsDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →